OPEN ACCESS Freely available online

ISSN: 2157-7560
Journal of
Vaccines & Vaccination

Short communication

Advancing Seasonal Protection Through Adjuvanted Influenza Vaccines

Richard Chernoff *

Department of Clinical Immunology, Eastwood University, Vancouver, Canada

DESCRIPTION

Influenza remains one of the most frequently occurring respiratory infections worldwide, affecting millions of people every year. Although many individuals recover without serious complications, influenza can lead to hospitalization and death among vulnerable populations, particularly older adults, individuals with chronic medical conditions, pregnant women, and young children. Vaccination continues to be the most effective public health measure for reducing the impact of seasonal influenza. Among the various influenza vaccine formulations available today, adjuvanted influenza vaccines have received considerable attention because of their ability to improve immune responses in specific populations.

An adjuvanted influenza vaccine contains not only influenza antigens but also an additional substance known as an adjuvant. The purpose of the adjuvant is to enhance the body's immune reaction to the vaccine. Influenza vaccines work by introducing antigens that resemble components of circulating influenza viruses. These antigens stimulate the immune system to produce antibodies capable of recognizing and responding to future viral exposure. In some individuals, particularly older adults, immune responses to conventional vaccines may be less effective due to age-related changes in immune function. The addition of an adjuvant helps increase immune activation and may improve protection against influenza infection.

The concept of vaccine adjuvants has been part of immunological research for many decades. Scientists observed that certain substances could strengthen immune responses when combined with vaccine antigens. Over time, various adjuvants were studied and incorporated into approved vaccines after extensive evaluation. In influenza vaccines, adjuvants are designed to stimulate immune cells at the site of injection and encourage a more effective response to the viral antigens present in the vaccine formulation.

One of the most widely used adjuvants in influenza vaccination is MF59, an oil-in-water emulsion composed of naturally occurring compounds. This adjuvant has been utilized in influenza vaccines intended primarily for older adults. Research has shown that MF59 can increase antibody production and improve the immune system's recognition of influenza antigens. By enhancing immune activity, adjuvanted vaccines may offer improved protection compared with some standard vaccine formulations, particularly among individuals whose immune systems respond less vigorously to vaccination.

Influenza viruses are characterized by frequent genetic changes. Small mutations accumulate over time, resulting in antigenic drift, which can alter viral surface proteins and reduce the effectiveness of existing immunity. Because of these continual changes, influenza vaccine formulations are updated regularly to match circulating strains as closely as possible. Adjuvanted vaccines may provide an additional advantage by stimulating antibody responses that recognize a wider range of viral variants. This broader immune activity can contribute to protection even when there is not a perfect match between vaccine strains and circulating viruses.

The use of adjuvanted influenza vaccines has become increasingly important as populations age in many countries. Demographic shifts have led to larger numbers of older adults, many of whom face elevated risks associated with influenza infection. Healthcare systems seek strategies that can reduce hospital admissions, complications, and mortality related to seasonal influenza outbreaks. By improving vaccine-induced immunity among high-risk groups, adjuvanted vaccines contribute to these public health objectives.

The global experience with influenza pandemics has further emphasized the importance of effective vaccination strategies. During periods when new influenza strains emerge and spread rapidly, vaccine production and distribution become critical components of public health preparedness. Adjuvants may play a useful role in pandemic response because they can enhance immune responses while allowing smaller quantities of antigen to be used in each vaccine dose. This characteristic may help increase vaccine availability during periods of high demand.

Scientific investigation continues to expand understanding of how adjuvants influence immune responses. Researchers are

Correspondence to: Richard Chernoff, Department of Clinical Immunology, Eastwood University, Vancouver, Canada, E-mail: richard.ch.@eastwood-ac.org

Received: 28-Jan-2026, Manuscript No. JVV-26-31896; **Editor assigned:** 30-Jan-2026, Pre QC No. JVV-26-31896 (PQ); **Reviewed:** 9-Feb-2026, QC No. JVV-26-31896; **Revised:** 16-Feb-2026, Manuscript No. JVV-26-31896 (R); **Published:** 23-Febs-2026, DOI: 10.35248/2157-7560.26.17.647.

Citation: Chernoff R (2026). Advancing Seasonal Protection Through Adjuvanted Influenza Vaccines. J Vaccines Vaccin. 17:647.

examining new adjuvant formulations, alternative vaccine technologies, and methods for improving long-term immunity. These studies aim to enhance vaccine performance across different age groups and health conditions. Advances in immunology, molecular biology, and vaccine manufacturing are expected to contribute to future improvements in influenza prevention.

CONCLUSION

Adjuvanted influenza vaccines represent an important development in the effort to reduce the burden of seasonal influenza. By strengthening immune responses, particularly among older adults and other vulnerable populations, these vaccines provide an additional option for disease prevention. Their use reflects decades of scientific research, clinical evaluation, and public health experience. As influenza viruses continue to circulate and evolve, adjuvanted vaccines will remain a valuable component of comprehensive vaccination strategies designed to protect individuals and communities from the consequences of influenza infection.

REFERENCES

1. Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017;35(4):513-520.
2. Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013;31(51):6122-6128.
3. Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, et al. Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals≥ 18 years of age. Rev Med Virol. 2023;33(3): e2329.
4. Beyer WE, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis. 1996;15(1):65-70.
5. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28(7):563-571.
6. Rabadan R, Robins H. Evolution of the influenza a virus: some new advances. Evol Bioinform Online. 2007; 3:117693430700300021.
7. Ali ST, Cowling BJ. Influenza virus: tracking, predicting, and forecasting. Annu Rev Public Health. 2021;42(1):43-57.
8. Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe. 2010 ;7(6): 440-451.
9. Cargnin Faccin F, Perez DR. Pandemic preparedness through vaccine development for avian influenza viruses. Hum Vaccin Immunother. 2024;20(1):2347019.
10. Orrico-Sánchez A, Valls-Arévalo Á, Garcés-Sánchez M, Aldeán JÁ, de Lejarazu Leonardo RO. Efficacy and effectiveness of influenza vaccination in healthy children. A review of current evidence. Enferm Infecc Microbiol Clin (Engl Ed). 2023; 41(7):396-406.